Charles River Laboratories International Inc. has announced the formation of a global, cross-functional Scientific Advisory Board to guide its strategic focus on New Approach Methodologies (NAMs). The company plans to advance the development, regulatory validation, and integration of NAMs into drug discovery and development programs. The Scientific Advisory Board, led by Dr. Namandjé N. Bumpus, will provide strategic guidance to enhance the predictability of efficacy and safety testing while aiming to reduce reliance on animal testing. Charles River intends to leverage internal and external expertise to foster innovation, address regulatory challenges, and support clients in validating and adopting alternative methods across the biopharmaceutical industry. The company views this as a long-term opportunity to lead the advancement and adoption of NAMs.